Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 3/20 | 0.54 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | IL1RN | P18510 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1891805 | 0.90 | ALDH1A1 (0.72) | FFAR4ALDH1A1GAASMN1; SMN2MEN1 | |
| SCHEMBL10182996 | 0.87 | ALDH1A1 (0.69) | FFAR4ALDH1A1GAASMN1; SMN2MEN1 | |
| SCHEMBL4901044 | 0.87 | ALDH1A1 (0.73) | FFAR4ALDH1A1GAASMN1; SMN2MEN1 | |
| SCHEMBL10618991 | 0.83 | FFAR4 (1.00) | FFAR4ALDH1A1GAASMN1; SMN2MEN1 | |
| SCHEMBL6570574 | 0.83 | ALDH1A1 (0.72) | FFAR4ALDH1A1GAASMN1; SMN2MEN1 | |
| SCHEMBL17557158 | 0.83 | FFAR4 (0.71) | FFAR4ALDH1A1GAASMN1; SMN2MEN1 | |
| SCHEMBL9749511 | 0.83 | FFAR4 (0.71) | FFAR4ALDH1A1GAASMN1; SMN2MEN1 | |
| SCHEMBL8026293 | 0.83 | FFAR4 (0.71) | FFAR4ALDH1A1GAASMN1; SMN2MEN1 | |
| SCHEMBL4968283 | 0.83 | ALDH1A1 (1.00) | ALDH1A1GAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5429681 | 0.81 | SMN1; SMN2 (0.67) | FFAR4ALDH1A1GAASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221178-A1 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221178-A1 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221178-A1 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| EP-1670790-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| EP-1670790-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007091950-A1 | BENZIMIDAZOLES AND IMIDAZOPYRIDINES USEFUL IN THE TREATMENT OF DISEASES OR DISORDERS ASSOCIATED WITH CANNABINOID RECEPTOR 2 (CB2) SUCH AS PAIN | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | WO | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
| EP-1673369-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-28 | — | — | EP | disclosed |
| EP-1670790-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030761-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030762-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
| EP-1220844-B1 | ARYL SULFONAMIDE-SUBSTITUTED BENZIMIDAZOL DERIVATIVES THEREOF AS TRYPTASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-04-09 | — | — | EP | disclosed |
| US-6365584-B1 | FOR PROPHYLAXIS AND THERAPY OF INFLAMMATORY AND/OR ALLERGIC DISEASES, LUNG FIBROSIS, FIBROSING ALVEOLITIS AND SCARRING, COLLAGENOSES SUCH AS LUPUS ERYTHEMATODES AND SCLERODERMIA AS WELL AS ARTERIOSCLEROSIS, PSORIASIS AND NEOPLASM | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | RB1, CYP2C19, ADRB3 | FFAR4 1486/4885ALDH1A1 165/4885GAA 1933/4885 |
| US-20080221178-A1 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof | TBXA2R, CYP2C19, CYP3A43 | FFAR4 1615/4885ALDH1A1 93/4885GAA 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.